A Hyderabad-based startup, Acubiosys, is leveraging artificial intelligence and nanotechnology to develop innovative therapies for autoimmune skin disorders and wound care. By integrating these advanced technologies with biomedical research, the company aims to create targeted, effective treatments for chronic conditions.
Acubiosys, incubated at the BRIC-CDFD Technology Incubator, employs AI algorithms to analyze extensive botanical databases and conducts three-dimensional molecular modeling to screen numerous plant-derived compounds. This process facilitates the identification of bioactive compounds that can effectively target inflammatory pathways associated with conditions like psoriasis, atopic dermatitis, and diabetic foot ulcers.
The startup has successfully commercialized two patented products: BOCUGL, aimed at managing skin disorders, and AZBECO, designed for chronic wound care. Both formulations utilize nanotechnology to enhance the delivery and efficacy of the active ingredients, ensuring deeper penetration through the skin barrier.
Acubiosys' approach not only addresses significant clinical challenges in dermatology but also contributes to India's biotechnology landscape. By focusing on affordable, evidence-based solutions, the startup is poised to make a meaningful impact on patient outcomes in the healthcare sector.